NCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07355010 2026-01-21
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT07266350 2025-12-05
A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
Chongqing University Cancer Hospital
Not yet recruiting
NCT07143292 2025-11-18
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06336954 2024-03-29
Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 2 Not yet recruiting
NCT06332950 2024-03-27
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting